Luiz Henrique César Vasconcelos

Prof. Dr. Luiz Henrique César Vasconcelos


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
IFIndyra Alencar Duarte Figueiredo
Indyra Alencar Duarte Figueiredo
SFSarah Rebeca Dantas Ferreira
Sarah Rebeca Dantas Ferreira
JFJayne Muniz Fernandes
Jayne Muniz Fernandes
PSPatricia Mirella da Silva
Patricia Mirella da Silva
LVLuiz Henrique César Vasconcelos
Luiz Henrique César Vasconcelos
FCFabiana de Andrade Cavalcante
Fabiana de Andrade Cavalcante
Asthma is one of the main non-communicable chronic diseases and affects a huge portion of the population. It is a multifactorial disease, classified into several phenotypes, being the allergic the most frequent. The pathophysiological mechanism of asthma involves a Th2-type immune response, with high concentrations of allergen-specific immunoglobulin E, eosinophilia, hyperreactivity and airway remodeling. These mechanisms are orchestrated by intracellular signaling from effector cells, such as lymphocytes and eosinophils. Ion channels play a fundamental role in maintaining the inflammatory response on asthma. In particular, transient receptor potential (TRP), stock-operated Ca2+ channels (SOCs), Ca2+-activated K+ channels (IKCa and BKCa), calcium-activated chloride channel (TMEM16A), cystic fibrosis transmembrane conductance regulator (CFTR), piezo-type mechanosensitive ion channel component 1 (PIEZO1) and purinergic P2X receptor (P2X). The recognition of the participation of these channels in the pathological process of asthma is important, as they become pharmacological targets for the discovery of new drugs and/or pharmacological tools that effectively help the pharmacotherapeutic follow-up of this disease, as well as the more specific mechanisms involved in worsening asthma.

9 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SFSarah Rebeca Dantas Ferreira
Sarah Rebeca Dantas Ferreira
RPRayane Fernandes Pessoa
Rayane Fernandes Pessoa
IFIndyra Alencar Duarte Figueiredo
Indyra Alencar Duarte Figueiredo
JLJoão Pedro Moura Lima
João Pedro Moura Lima
TMThayna Maria Costa Fernandes de Moura
Thayna Maria Costa Fernandes de Moura
FCFabiana de Andrade Cavalcante
Fabiana de Andrade Cavalcante
The obesity-exacerbated asthma phenotype is characterized by more severe asthma symptoms and glucocorticoid resistance. The aim of this study was to standardize an obesity-exacerbated asthma model by a high glycemic level index (HGLI) diet and ovalbumin (OVA) sensitization and challenges in Wistar rats. Animals were divided into groups: control (Ctrl), obese (Ob), asthmatic (Asth), obese asthmatic (Ob + Asth) and obese asthmatic treated with dexamethasone (Ob + Asth + Dexa), and in vivo and in vitro functional and morphological parameters were measured. After HGLI consumption, there was an increase in body weight, fasting blood glucose, abdominal circumferences, body mass index and adiposity index. Respiratory function showed a reduction in pulmonary tidal volume and ventilation. In isolated tracheas, carbachol showed an increase in contractile efficacy in the Ob, Ob + Asth and Ob + Asth + Dexa, but mostly on Ob + Asth. Histological analysis of lungs showed peribronchovascular inflammation and smooth muscle hypertrophy and extracellular remodeling on Ob + Asth and Ob + Asth + Dexa. An obesity-exacerbated asthma model was successfully established. Therefore, this model allows further molecular investigations and the search for new therapies for the treatment and relief of symptoms of patients with obesity-induced resistant asthma.

6 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
IFIndyra Alencar Duarte Figueiredo
Indyra Alencar Duarte Figueiredo
AMAlissa Maria Martins
Alissa Maria Martins
ACAlexya Cavalcanti
Alexya Cavalcanti
JFJayne Muniz Fernandes
Jayne Muniz Fernandes
LGLudmila Emilly da Silva Gomes
Ludmila Emilly da Silva Gomes
FCFabiana De Andrade Cavalcante
Fabiana De Andrade Cavalcante
Background/Objectives: Lauric acid (LA), a medium-chain fatty acid, is a promising drug for asthma treatment. This study evaluated the toxicity of repeated doses and the effect of LA on pulmonary ventilation and tracheal reactivity in asthmatic Wistar rats and identified possible molecular targets of LA action in silico. Methods: The rats were divided into control (CG) and LA-treated groups at 100 mg/kg (AL100G) for toxicity analysis. Pulmonary ventilation and tracheal reactivity were assessed in the control (CG), asthmatic (AG), asthmatic treated with LA at 25, 50, or 100 mg/kg (AAL25G, AAL50G, and AAL100G), and dexamethasone-treated groups (ADEXAG). Results: The results showed that LA at a dose of 100 mg/kg did not cause death or toxicity. A pulmonary ventilation analysis indicated that AG had reduced minute volume, which was prevented in AAL25G. LA at all doses prevented carbachol-induced tracheal hyper-responsiveness and reduced the relaxing effect of aminophylline, as observed in AG. An in silico analysis revealed that LA had a good affinity for nine proteins (β2-adrenergic receptor, CaV, BKCa, KATP, adenylyl cyclase, PKG, eNOS, iNOS, and COX-2). Conclusions: LA at 100 mg/kg has low toxicity, prevents hyper-responsiveness in an asthma model in rats, and acts as a multitarget compound with a good affinity for proteins related to airway hyper-responsiveness.

22 July 2022 in Marine Drugs
Verified
Journal Article
Open access
PDF file
ISIara Leão Luna de Souza
Iara Leão Luna de Souza
BBBárbara Cavalcanti Barros
Bárbara Cavalcanti Barros
EFElba dos Santos Ferreira
Elba dos Santos Ferreira
FQFernando Ramos Queiroga
Fernando Ramos Queiroga
LVLuiz Henrique César Vasconcelos
Luiz Henrique César Vasconcelos
PSPatricia Mirella da Silva
Patricia Mirella da Silva
Erectile dysfunction (ED) is the inability to achieve and/or maintain a penile erection sufficient for sexual satisfaction. Currently, many patients do not respond to the pharmacotherapy. The effects of a supplementation with Spirulina platensis, were evaluated in a model of ED induced by hypercaloric diet consumption. Wistar rats were divided into groups fed with standard diet (SD) or hypercaloric diet (HD) and supplemented with this alga at doses of 25, 50 or 100 mg/kg. Experimental adiposity parameters and erectile function were analyzed. In SD groups, Spirulina platensis reduced food intake, final body mass and adiposity index, and increased the total antioxidant capacity (TAC) of adipose tissue. However, no change was observed in erectile function. In the HD group, without Spirulina supplementation, a decrease in food intake was observed, in addition to an increase of final body mass, weight gain, adipose reserves, and adiposity index. Additionally, reduction in the number and increase in the latency of penile erection and adipose malondialdehyde levels, as well as a reduction in TCA was noted. Furthermore, cavernous contractility was increased, and the relaxing response was decreased. Interestingly, these deleterious effects were prevented by the algae at doses of 25, 50 and/or 100 mg/kg. Therefore, the supplementation with S. platensis prevents damages associated to a hypercaloric diet consumption and emerges as an adjuvant the prevention of ED.

5 January 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
IFIndyra Alencar Duarte Figueiredo
Indyra Alencar Duarte Figueiredo
AMAlissa Martins
Alissa Martins
ACAlexya Cavalcanti
Alexya Cavalcanti
JFJayne Fernandes
Jayne Fernandes
LGLudmila Gomes
Ludmila Gomes
FCFabiana Cavalcante
Fabiana Cavalcante
Lauric acid, or dodecanoic acid, a medium-chain fatty acid, prevents alterations in pulmonary ventilation and tracheal hyperresponsiveness in Wistar rats with allergic asthma induced by ovalbumin (OVA). Therefore, the aim was to evaluate the mechanism of action of lauric acid (LA) in its preventive effect on changes caused by asthma. Rats were randomly divided into a control group (CG), an asthmatic group (AG), and an asthmatic lauric acid 25-mg/kg group (ALA25G). Rats in the AG and ALA25G groups were sensitized and challenged with OVA. For the experimental protocols, the trachea and lungs were isolated after euthanasia. A reduction in the contractile reactivity to CCh was observed in the asthmatic group in the presence of indomethacin, zileuton, L-NAME, apocynin, and tempol, inhibitors of COX, 5-LOX, NOS, NADPH oxidase, and a mimetic of superoxide dismutase (SOD), respectively. In the ALA25G, the contractile reactivity was reduced in the presence of indomethacin, L-NAME, and apocynin. Furthermore, an increase in lipid peroxidation (MDA) and nitrite levels and a reduction of reduced glutathione (GSH) levels and SOD activity were observed in the pulmonary homogenate of the AG. Treatment with lauric acid at a dose of 25 mg/kg prevented all of these alterations, except for the reduction in GSH levels. In conclusion, LA reduces tracheal hyperresponsiveness in Wistar rats with allergic asthma by negatively modulating both the COX and NO pathways and oxidative stress imbalance.